The webinar will feature a presentation from Key Opinion Leader (KOL) Eric D. Donnenfeld, MD (OCLI Vision) who will discuss the current treatment landscape and unmet medical need in treating patients with dry eye disease.

Palatin Technologies’ Chief Medical Officer Michael Raizman, MD will also discuss their Phase 3 trial for PL9643 in patients with dry eye disease. MELODY-1 clinical study is a multi-center, randomized, double–masked and vehicle–controlled study evaluating the safety and efficacy of the melanocortin agonist, PL9643 ophthalmic solution, compared to vehicle in subjects with dry eye disease (DED). The study is designed to enroll up to 400 patients at multiple U.S. sites, and top-line results are currently expected second half calendar 2022.

A question and answer session will follow.